Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response

Leukemia Research

Volumn 38, Issue 5, 2014, Pages 581-585

  Iacobucci, Ilaria ^a   Lonetti, Annalisa ^b   Venturi, Claudia ^a   Ferrari, Anna ^a   Papayannidis, Cristina ^a   Ottaviani, Emanuela ^a   Abbenante, Maria Chiara ^a   Paolini, Stefania ^a   Bresciani, Paola ^c   Potenza, Leonardo ^c   Parisi, Sarah ^a   Cattina, Federica ^a,d   Soverini, Simona ^a   Russo, Domenico ^d   Luppi, Mario ^c   Martinelli, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

BCR ABL1; Leukemia; Minimal residual disease

Indexed keywords

BCR-ABL1; LEUKEMIA; MINIMAL RESIDUAL DISEASE;

FUSION PROTEINS, BCR-ABL; HUMANS; NANOTECHNOLOGY; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84899097901     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.02.005     Document Type: Article

References (18)

1. Vignetti M., Fazi P., Cimino G., Martinelli G., Di Raimondo F., Ferrara F., et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109(May (9)):3676-3678.
2. Ottmann O., Dombret H., Martinelli G., Simonsson B., Guilhot F., Larson R.A., et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110(October (7)):2309-2315.
3. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354(January (24)):2531-2541.
4. Wong S.F. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia. J Oncol Pharm Pract 2009 Mar, 15(1):17-27.
5. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, June (354)(24):2542-2551.
6. Foa R., Vitale A., Vignetti M., Meloni G., Guarini A., De Propris M.S., et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011, December (118)(25):6521-6528.
7. Lee H.J., Thompson J.E., Wang E.S., Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2010, 117(8):1583-1594.
8. Radich J., Gehly G., Lee A., Avery R., Bryant E., Edmands S., et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997, April (89)(7):2602-2609.
9. Wassmann B., Pfeifer H., Stadler M., Bornhauser M., Bug G., Scheuring U.J., et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005, July (106)(2):458-463.
10. Lee S., Kim D.W., Cho B., Kim Y.J., Kim Y.L., Hwang J.Y., et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003, January (120)(1):145-153.
11. Muller M.C., Saglio G., Lin F., Pfeifer H., Press R.D., Tubbs R.R., et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica 2007, July (92)(7):970-973.
12. Cross N.C. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, September (22)(3):355-365.
13. Sanders R., Huggett J.F., Bushell C.A., Cowen S., Scott D.J., Foy C.A. Evaluation of digital PCR for absolute DNA quantification. Anal Chem 2011, Septemner (83)(17):6474-6484.
14. Iacobucci I., Rosti G., Amabile M., Poerio A., Soverini S., Cilloni D., et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 2006, January (24)(3):454-459.
15. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, December (17)(12):2318-2357.
16. Gabert J. Detection of recurrent translocations using real time PCR; assessment of the technique for diagnosis and detection of minimal residual disease. Haematologica 1999, June (84)(Suppl. EHA-4):107-109.
17. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, February (1)(8476):307-310.
18. Spitali P., Heemskerk H., Vossen R.H., Ferlini A., den Dunnen J.T., t Hoen P.A., et al. Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy. Lab Invest 2010, September (90)(9):1396-1402.